SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] S-1: (Original Filing)

[CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to Be Registered Amount to Be Registered] [UNDERWRITING AGREEMENT between SKYSTAR BIO-PHARMACEUTICAL COMPANY and RODMAN & RENSHAW, LLC as Representative SKYSTAR BIO-PHARMACEUTICAL COMPANY UNDERWRITING AGREEMENT New York, New York ___________ __, 2010 Rodman & Renshaw, LLC th 1251 Avenue of the Americas, 20 New York, New York 10020 Ladies and Gentlemen: Company Representative Underwriters Underwriter 1. Purchase and Sale of Securities. 1.1 Firm Securities 1.1.1. Nature and] [Form of Representative’s Option Agreement THE REGISTERED HOLDER OF THIS PURCHASE OPTION BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE OPTION EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE OPTION AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE OPTION FOR A PERIOD OF ONE HUNDRED] [RICHARDSON & PATEL LLP 10900 Wilshire Boulevard Suite 500 Los Angeles, California 90024 Telephone (310) 208-1183 Facsimile (310) 208-1154 ___________________, 2010 SKYSTAR BIO-PHARMACEUTICAL COMPANY Rm. 10601, Jiezuo Plaza, No.4, Fenghui Road South, Gaoxin District, Xian Province, P.R. China Re: SKYSTAR BIO-PHARMACEUTICAL COMPANY Ladies and Gentlemen: In connection with this opinion, we have examined originals or copies of the registration statement,] [Consent of Independent Registered Public Accounting Firm To the Board of Directors Skystar Bio-Pharmaceutical Company We consent to the use of our report dated March 31, 2010, with respect to the consolidated financial statements of Skystar Bio-Pharmaceutical Company and Subsidiaries (the “Company”) as of December 31, 2009 and 2008 and for the related statements of income and other comprehensive income,]

By | 2016-03-01T06:05:47+00:00 June 1st, 2010|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] S-1: CALCULATION OF REGISTRATION FEE Title of Each Class

[CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to Be Registered Amount to Be Registered] [UNDERWRITING AGREEMENT between SKYSTAR BIO-PHARMACEUTICAL COMPANY and RODMAN & RENSHAW, LLC as Representative SKYSTAR BIO-PHARMACEUTICAL COMPANY UNDERWRITING AGREEMENT New York, New York ___________ __, 2010 Rodman & Renshaw, LLC th 1251 Avenue of the Americas, 20 New York, New York 10020 Ladies and Gentlemen: Company Representative Underwriters Underwriter 1. Purchase and Sale of Securities. 1.1 Firm Securities 1.1.1. Nature and] [Form of Representative’s Option Agreement THE REGISTERED HOLDER OF THIS PURCHASE OPTION BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE OPTION EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE OPTION AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE OPTION FOR A PERIOD OF ONE HUNDRED] [RICHARDSON & PATEL LLP 10900 Wilshire Boulevard Suite 500 Los Angeles, California 90024 Telephone (310) 208-1183 Facsimile (310) 208-1154 ___________________, 2010 SKYSTAR BIO-PHARMACEUTICAL COMPANY Rm. 10601, Jiezuo Plaza, No.4, Fenghui Road South, Gaoxin District, Xian Province, P.R. China Re: SKYSTAR BIO-PHARMACEUTICAL COMPANY Ladies and Gentlemen: In connection with this opinion, we have examined originals or copies of the registration statement,] [Consent of Independent Registered Public Accounting Firm To the Board of Directors Skystar Bio-Pharmaceutical Company We consent to the use of our report dated March 31, 2010, with respect to the consolidated financial statements of Skystar Bio-Pharmaceutical Company and Subsidiaries (the “Company”) as of December 31, 2009 and 2008 and for the related statements of income and other comprehensive income,]

By | 2016-03-01T06:06:43+00:00 June 1st, 2010|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments

CCM [Concord Medical Services] 6-K: (Original Filing)

[Concord Medical Announces First Quarter 2010 Financial Results 1 BEIJING, May 27, 2010 — Concord Medical Services Holdings Limited (“Concord Medical” or the “Company”) (NYSE: CCM), the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited financial results for the first quarter ended March 31, 2010 First Quarter Fiscal 2010 Highlights •] [FORM 6-K CONCORD MEDICAL SERVICES HOLDINGS LIMITED 18/F, Tower A, Global Trade Center þ o Form 20-F o o o þ Yes 82- N/A TABLE OF CONTENTS EX-99.1 TABLE OF CONTENTS 2 CONCORD MEDICAL SERVICES HOLDINGS LIMITED Jianyu Yang Director, Chief Executive Officer and President 3 6-K 1 h04269e6vk.htm FORM 6-K]

WX [WuXi PharmaTech (Cayman)] 6-K: (Original Filing)

[Form 6-K TABLE OF CONTENTS Page 3 4 2 WuXi PharmaTech (Cayman) Inc. Ge Li Chairman and CEO 3 ACQUISITION PROPOSED—YOUR VOTE IS VERY IMPORTANT Dear Shareholder: — — — You are cordially invited to the upcoming special meeting of shareholders of Charles River to be held on [ in vivo — — — — [ — [ — []

By | 2016-04-02T20:03:41+00:00 June 1st, 2010|Categories: Chinese Stocks, SEC Original, WX|Tags: , , , , , |0 Comments

CCM [Concord Medical Services] 6-K: Concord Medical Announces First Quarter 2010 Financial Results

[Concord Medical Announces First Quarter 2010 Financial Results 1 BEIJING, May 27, 2010 — Concord Medical Services Holdings Limited (“Concord Medical” or the “Company”) (NYSE: CCM), the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited financial results for the first quarter ended March 31, 2010 First Quarter Fiscal 2010 Highlights •] [FORM 6-K CONCORD MEDICAL SERVICES HOLDINGS LIMITED 18/F, Tower A, Global Trade Center þ o Form 20-F o o o þ Yes 82- N/A TABLE OF CONTENTS EX-99.1 TABLE OF CONTENTS 2 CONCORD MEDICAL SERVICES HOLDINGS LIMITED Jianyu Yang Director, Chief Executive Officer and President 3 6-K 1 h04269e6vk.htm FORM 6-K]

WX [WuXi PharmaTech (Cayman)] 6-K: Form 6-K TABLE OF CONTENTS Page 3 4

[Form 6-K TABLE OF CONTENTS Page 3 4 2 WuXi PharmaTech (Cayman) Inc. Ge Li Chairman and CEO 3 ACQUISITION PROPOSED—YOUR VOTE IS VERY IMPORTANT Dear Shareholder: — — — You are cordially invited to the upcoming special meeting of shareholders of Charles River to be held on [ in vivo — — — — [ — [ — []

By | 2016-04-02T20:04:30+00:00 June 1st, 2010|Categories: Chinese Stocks, Webplus ver, WX|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] S-1: (Original Filing)

[CALCULATION OF REGISTRATION FEE TitleofEachClassofSecuritiestoBeRegistered AmounttoBe Registered ProposedMaximumgregateOffering (1) Price Amountof RegistrationFee (2) Shares ofmmon Stock, $.001 par value $ 28,750,000 $ 2,049.88 (3) (4) Underwritersmmon Stock Purchase Option 1 option $ 100 $ - Shares ofmmon Stock underlying Underwritersmmon Stock Purchase Option $ 781,250 $] [UNDERWRITINGREEMENT betweenYSTAR BIO-PHARMACEUTICALMPANY and RODMAN & RENSHAW, RepresentativeYSTAR BIO-PHARMACEUTICALMPANY UNDERWRITINGREEMENT New York, New York ___________ __, 2010 Rodman & Renshaw, th 1251 Avenue of the Americas, 20 New York, New York 10020 Ladies and Gentlemen:mpany Representative Underwriters Underwriter 1. Purchase andle of Securities.] [Form of Representatives Optionreement THE REGISTERED HOLDER OF THIS PURCHASE OPTION BY ITS ACCEPTANCE HEREOF,REES THAT IT WILL NOT SELL, TRANSFER ORSIGN THIS PURCHASE OPTION EXCEPT HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE OPTIONREES THAT IT WILL NOT SELL, TRANSFER,SIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE OPTION FOR A PERIOD OF ONE HUNDRED EIGHTYYS] [RICHARDSON & PATEL 10900 Wilshire Boulevard Suite 500 Los Angeles,lifornia 90024 Telephone (310) 208-1183 Facsimile (310) 208-1154 ___________________, 2010YSTAR BIO-PHARMACEUTICALMPANY Rm. 10601, Jiezuo Plaza, No.4, Fenghui Road South, Gaoxin District, Xian Province, P.R. China Re:YSTAR BIO-PHARMACEUTICALMPANY Ladies and Gentlemen: Innnection with this opinion, we have examined originals orpies of the registration statement, the proceedings of] [Consent of Independent Registered Public Accounting Firm To the Board of Directorsystar Bio-Pharmaceuticalmpany Wensent to the use of our reportted March 31, 2010, with respect to thensolidated financial statements ofystar Bio-Pharmaceuticalmpany and Subsidiaries (thempany) of December 31, 2009 and 2008 and for the related statements ofome and othermprehensiveome, shareholders equity andsh flows for each of]

By | 2016-02-05T04:14:39+00:00 June 1st, 2010|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments
Skip to toolbar